Literature DB >> 9886886

Role of the sympathetic nervous system in human hypertension.

G Grassi1.   

Abstract

Animal studies have shown conclusively that sympathetic neural factors are involved in the development and/or maintenance of high blood pressure. Whether this is also the case for human hypertension has been documented less conclusively, owing to technical difficulties in assessing human adrenergic function. Recent studies have used sophisticated and sensitive techniques to evaluate sympathetic activity in humans, e.g. the norepinephrine spillover method and the microneurographic quantification of sympathetic nerve traffic, allowing documentation of the participation of adrenergic mechanisms in the early and late phases of the hypertensive process. Evidence has been also provided that the activation of the sympathetic nervous system (1) is peculiar to the essential hypertensive state, (2) parallels the degree of the blood pressure elevation, (3) is triggered by reflex and humoral mechanisms and (4) may exert deleterious metabolic and cardiovascular effects, accelerating the progression of the end organ damage accompanying hypertension. These findings explain why non-pharmacological and pharmacological approaches to the treatment of hypertension should be aimed not only at lowering elevated blood pressure values but also at exerting sympathoinhibitory effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9886886     DOI: 10.1097/00004872-199816121-00019

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  65 in total

Review 1.  Autonomic dysfunction in programmed hypertension.

Authors:  Hasthi U Dissanayake; Michael R Skilton; Jaimie W Polson
Journal:  J Hum Hypertens       Date:  2018-12-05       Impact factor: 3.012

2.  Protein kinase CK2 increases glutamatergic input in the hypothalamus and sympathetic vasomotor tone in hypertension.

Authors:  Zeng-You Ye; De-Pei Li; Li Li; Hui-Lin Pan
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

Review 3.  Sympathetic deactivation as a goal of nonpharmacologic and pharmacologic antihypertensive treatment: rationale and options.

Authors:  Guido Grassi
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

4.  A case of acute myocardial infarction due to the use of cayenne pepper pills.

Authors:  Muhammet Rasit Sayin; Turgut Karabag; Sait Mesut Dogan; Ibrahim Akpinar; Mustafa Aydin
Journal:  Wien Klin Wochenschr       Date:  2012-04-20       Impact factor: 1.704

Review 5.  Blood flow restriction training and the exercise pressor reflex: a call for concern.

Authors:  Marty D Spranger; Abhinav C Krishnan; Phillip D Levy; Donal S O'Leary; Scott A Smith
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-04       Impact factor: 4.733

Review 6.  The role of cardiac autonomic function in hypertension and cardiovascular disease.

Authors:  Paolo Palatini; Stevo Julius
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

7.  Sympathetic reactivity in young women with a family history of hypertension.

Authors:  Jody L Greaney; Evan L Matthews; Megan M Wenner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-13       Impact factor: 4.733

Review 8.  Mild hyperbaric oxygen: mechanisms and effects.

Authors:  Akihiko Ishihara
Journal:  J Physiol Sci       Date:  2019-05-06       Impact factor: 2.781

Review 9.  Neuroimmune communication in hypertension and obesity: a new therapeutic angle?

Authors:  Annette D de Kloet; Eric G Krause; Peng D Shi; Jasenka Zubcevic; Mohan K Raizada; Colin Sumners
Journal:  Pharmacol Ther       Date:  2013-02-28       Impact factor: 12.310

10.  Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.

Authors:  J Michael Gaziano; Anthony H Cincotta; Christopher M O'Connor; Michael Ezrokhi; Dean Rutty; Z J Ma; Richard E Scranton
Journal:  Diabetes Care       Date:  2010-03-23       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.